title: Clinical utility of the risperidone formulations in the management of schizophrenia.
abstract: Risperidone is one of the early second-generation antipsychotics that came into the limelight in the early 1990s. Both the oral and long-acting injectable formulations have been subject to numerous studies to assess their safety, efficacy, and tolerability. Risperidone is currently one of the most widely prescribed antipsychotic medications, used for both acute and long-term maintenance in schizophrenia. Risperidone has better efficacy in the treatment of psychotic symptoms than placebo and possibly many first-generation antipsychotics. Risperidone fares better than placebo and first-generation antipsychotics in the treatment of negative symptoms. Risperidone's long acting injectable preparation has been well tolerated and is often useful in patients with medication nonadherence. Risperidone has a higher risk of hyperprolactinemia comparable to first-generation antipsychotics (FGAs) but fares better than many second-generation antipsychotics with regards to metabolic side effects. In this article, we briefly review the recent literature exploring the role of risperidone formulations in schizophrenia, discuss clinical usage, and highlight the controversies and challenges associated with its use.
authors.affiliation: University of Virginia Health System, Charlottesville, VA, USA.
authors.forename: Vishal
authors.initials: V
authors.lastname: Madaan
authors.forename: Durga P
authors.initials: DP
authors.lastname: Bestha
authors.forename: Venkata
authors.initials: V
authors.lastname: Kolli
authors.forename: Saurabh
authors.initials: S
authors.lastname: Jauhari
authors.forename: Roger C
authors.initials: RC
authors.lastname: Burket
references.citation: Am J Psychiatry. 2004 Mar;161(3):414-25
references.pmid: 14992963
references.citation: Neuropsychopharmacology. 2008 Aug;33(9):2061-79
references.pmid: 18046305
references.citation: Br J Psychiatry Suppl. 2009 Nov;52:S13-9
references.pmid: 19880912
references.citation: Am J Psychiatry. 2006 Oct;163(10):1821-5
references.pmid: 17012695
references.citation: J Am Geriatr Soc. 1999 Jun;47(6):716-9
references.pmid: 10366172
references.citation: Eur J Health Econ. 2010 Dec;11(6):585-94
references.pmid: 20084535
references.citation: J Psychiatry Neurosci. 2000 Mar;25(2):137-53
references.pmid: 10740987
references.citation: Neuropsychiatr Dis Treat. 2010 Dec 22;7:19-26
references.pmid: 21326651
references.citation: South Med J. 2007 Aug;100(8):771-2
references.pmid: 17713300
references.citation: Int Clin Psychopharmacol. 2010 May;25(3):149-54
references.pmid: 20305567
references.citation: Child Adolesc Psychiatr Clin N Am. 2006 Jan;15(1):177-206
references.pmid: 16321730
references.citation: Schizophr Bull. 2009 Mar;35(2):458-68
references.pmid: 18436527
references.citation: J Child Adolesc Psychopharmacol. 2009 Dec;19(6):611-21
references.pmid: 20035579
references.citation: Eur Neuropsychopharmacol. 2005 Jan;15(1):111-7
references.pmid: 15572280
references.citation: Cochrane Database Syst Rev. 2011 Jan 19;(1):CD006626
references.pmid: 21249678
references.citation: Cochrane Database Syst Rev. 2003;(2):CD000440
references.pmid: 12804396
references.citation: CNS Drugs. 2009;23(6):477-92
references.pmid: 19480467
references.citation: Hum Psychopharmacol. 2010 Jun-Jul;25(4):281-97
references.pmid: 20521318
references.citation: BMJ. 2006 Jul 29;333(7561):224
references.pmid: 16825203
references.citation: Drugs Today (Barc). 2009 Jan;45(1):55-62
references.pmid: 19271032
references.citation: J Psychopharmacol. 2011 Jun;25(6):744-54
references.pmid: 21292922
references.citation: Schizophr Res. 2010 Nov;123(2-3):225-33
references.pmid: 20692814
references.citation: Lancet. 2009 Jan 3;373(9657):31-41
references.pmid: 19058842
references.citation: Am J Psychiatry. 2009 Feb;166(2):152-63
references.pmid: 19015230
references.citation: J Clin Psychopharmacol. 2010 Oct;30(5):531-40
references.pmid: 20814320
references.citation: Cochrane Database Syst Rev. 2009 Oct 07;(4):CD007474
references.pmid: 19821422
references.citation: Arch Gen Psychiatry. 2003 Jun;60(6):553-64
references.pmid: 12796218
references.citation: Hum Psychopharmacol. 2009 Apr;24(3):233-8
references.pmid: 19330802
references.citation: J Clin Psychopharmacol. 2006 Dec;26(6):571-8
references.pmid: 17110813
references.citation: Cochrane Database Syst Rev. 2009 Jul 08;(3):CD006324
references.pmid: 19588385
references.citation: Clin Ther. 2008 Sep;30(9):1565-89
references.pmid: 18840365
references.citation: Can J Psychiatry. 2006 Jul;51(8):531-9
references.pmid: 16933590
references.citation: Psychopharmacology (Berl). 1994 Feb;114(1):9-23
references.pmid: 7531353
references.citation: Am J Psychiatry. 2003 Jun;160(6):1125-32
references.pmid: 12777271
references.citation: Mol Psychiatry. 2009 Apr;14(4):429-47
references.pmid: 18180760
references.citation: Cochrane Database Syst Rev. 2000;(2):CD000440
references.pmid: 10796543
references.citation: J Clin Psychiatry. 2004 Feb;65(2):267-72
references.pmid: 15003083
references.citation: Clin Ther. 2003 Jun;25(6):1687-99
references.pmid: 12860492
references.citation: Cochrane Database Syst Rev. 2010 Jan 20;(1):CD006918
references.pmid: 20091611
references.citation: Arch Gen Psychiatry. 2003 May;60(5):458-64
references.pmid: 12742866
references.citation: J Clin Psychiatry. 1998 Dec;59(12):644-56
references.pmid: 9921698
references.citation: Schizophr Res. 2010 Feb;116(2-3):101-6
references.pmid: 19959338
references.citation: J Child Adolesc Psychopharmacol. 2005 Dec;15(6):885-92
references.pmid: 16379508
references.citation: J Am Acad Child Adolesc Psychiatry. 1995 Oct;34(10):1292-6
references.pmid: 7592266
references.citation: J Child Adolesc Psychopharmacol. 1998;8(2):133-41
references.pmid: 9730079
references.citation: J Clin Psychopharmacol. 2008 Apr;28(2):210-3
references.pmid: 18344732
references.citation: Neuropsychobiology. 2010;62(2):81-6
references.pmid: 20523078
references.citation: Psychiatr Clin North Am. 1985 Dec;8(4):793-814
references.pmid: 3878510
references.citation: Br J Psychiatry Suppl. 2009 Nov;52:S29-36
references.pmid: 19880914
references.citation: J Clin Psychiatry. 2009 Jul;70(7):1041-50
references.pmid: 19653979
references.citation: Curr Med Res Opin. 2010 Mar;26(3):501-9
references.pmid: 20014981
references.citation: Hum Psychopharmacol. 2002 Mar;17(2):95-8
references.pmid: 12404698
references.citation: Nat Rev Drug Discov. 2003 Apr;2(4):315-20
references.pmid: 12669030
references.citation: Arch Gen Psychiatry. 2002 Apr;59(4):337-45
references.pmid: 11926934
references.citation: Pharmacopsychiatry. 2006 Nov;39(6):209-12
references.pmid: 17124642
references.citation: Arch Gen Psychiatry. 2005 Sep;62(9):961-70
references.pmid: 16143728
references.citation: Clin Ther. 2009 Jun;31 Pt 1:1345-59
references.pmid: 19698898
references.citation: CNS Drugs. 2009 Aug;23(8):649-59
references.pmid: 19594194
references.citation: Harv Rev Psychiatry. 2007 Sep-Oct;15(5):245-58
references.pmid: 17924259
references.citation: BMJ. 2000 Dec 2;321(7273):1371-6
references.pmid: 11099280
references.citation: Br J Psychiatry. 2008 Jun;192(6):406-11
references.pmid: 18515889
references.citation: J Am Acad Child Adolesc Psychiatry. 1997 May;36(5):694-700
references.pmid: 9136505
references.citation: Prog Neuropsychopharmacol Biol Psychiatry. 2011 Jan 15;35(1):208-11
references.pmid: 21095214